Core Insights - Alpha Cognition Inc. (NASDAQ: ACOG) has shown significant growth in the commercialization of its product ZUNVEYL® during Q3 2025, particularly in the U.S. long-term care (LTC) sector [1][7] - The company reported a 102% sequential increase in pharmacy orders, with over 600 nursing homes now covered and a prescriber base exceeding 500 clinicians [1][7] - Revenue for the quarter reached $2.8 million, driven by $2.3 million in net product sales from ZUNVEYL and $0.5 million in licensing revenue, indicating strong sequential growth [7] Company Performance - ZUNVEYL's launch momentum is accelerating, supported by a differentiated cognitive and behavioral profile and favorable tolerability signals observed in real-world use [1] - The LTC-focused field team is actively reinforcing the product's benefits, contributing to evidence of durable adoption and repeat ordering behavior in high-volume facilities [1] - Pro forma cash stands at approximately $73.2 million following an equity raise in October, providing about two years of operational runway at planned spending levels, bolstered by a $75 million ATM facility [7]
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025